Table 4 Interferon (IFN) pathway activation in patients with refractory inflammatory myopathies
PatientDiagnosisResponseType I IFN activity in sera, before treatmentType I IFN activity in sera, after treatment p = 0.037MxA expression in muscle tissue, before treatmentMxA expression in muscle tissue, after treatment p = 0.05
1PMImproved2.5503.90.64
2PMImproved0.00.110.240.64
3PMWorse0.00.380.032.05
4PMWorse1.384.060.150.24
5PMDropped out7.178.85NANA
6DMUnchanged0.211.80.160.4
7DMDropped outNANANANA
8DMDropped outNANANANA
9DMDropped out/worseNANANANA
10IBMImproved03.91.330.9
11IBMUnchanged4.034.440.370.56
12IBMUnchanged05.31.353.14
13IBMUnchanged0.050NANA
  • DM, dermatomyositis; IBM, inclusion body myositis; PM, polymyositis; MxA, intracellular antiviral protein (a marker for IFNα) expression in muscle tissue; NA, not analysed.